These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 23525615)

  • 21. Performance Assessment of a Multifaceted Unfractionated Heparin Dosing Protocol in Adult Patients on Extracorporeal Membrane Oxygenator.
    Al-Jazairi A; Raslan S; Al-Mehizia R; Dalaty HA; De Vol EB; Saad E; Alanazi M; Owaidah T
    Ann Pharmacother; 2021 May; 55(5):592-604. PubMed ID: 32959678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anticoagulation Monitoring with Activated Partial ThromboPlastin Time and Anti-Xa Activity in Intensive Care Unit Patients: Interest of Thrombin Generation Assay.
    Billoir P; Elie T; Levy JH; Besnier E; Dureuil B; Veber B; Le Cam-Duchez V; Clavier T
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accuracy of aPTT monitoring in critically ill patients treated with unfractionated heparin.
    van Roessel S; Middeldorp S; Cheung YW; Zwinderman AH; de Pont AC
    Neth J Med; 2014 Jul; 72(6):305-10. PubMed ID: 25319855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of a chromogenic assay to measure the factor Xa inhibitory activity of unfractionated heparin in canine plasma.
    Brooks MB
    Vet Clin Pathol; 2004; 33(4):208-14. PubMed ID: 15570557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Age is a determinant factor for measures of concentration and effect in children requiring unfractionated heparin.
    Newall F; Ignjatovic V; Johnston L; Summerhayes R; Lane G; Cranswick N; Monagle P
    Thromb Haemost; 2010 May; 103(5):1085-90. PubMed ID: 20174762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of anti-Xa and activated partial thromboplastin time monitoring for heparin dosing in patients with cirrhosis.
    Fuentes A; Gordon-Burroughs S; Hall JB; Putney DR; Monsour HP
    Ther Drug Monit; 2015 Feb; 37(1):40-4. PubMed ID: 24901494
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of unfractionated heparin protocols using antifactor Xa monitoring or activated partial thrombin time monitoring.
    Frugé KS; Lee YR
    Am J Health Syst Pharm; 2015 Sep; 72(17 Suppl 2):S90-7. PubMed ID: 26272899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inaccuracy of a "spiked curve" for monitoring unfractionated heparin therapy.
    Gausman JN; Marlar RA
    Am J Clin Pathol; 2011 Jun; 135(6):870-6. PubMed ID: 21571960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interlaboratory variation in heparin monitoring: Lessons from the Quality Management Program of Ontario coagulation surveys.
    Cuker A; Raby A; Moffat KA; Flynn G; Crowther MA
    Thromb Haemost; 2010 Oct; 104(4):837-44. PubMed ID: 20664895
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monitoring heparin therapy: relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples.
    van den Besselaar AM; Meeuwisse-Braun J; Bertina RM
    Thromb Haemost; 1990 Feb; 63(1):16-23. PubMed ID: 2339357
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Theophylline adenosine dipyridamole (CTAD) and citrate evaluation to survey unfractionated heparin treatment: a delayed centrifugation validation for anti-Xa measurement?].
    Billoir P; Clavier T; Guilbert A; Barbay V; Chrétien MH; Fresel M; Abriou C; Girault C; Le Cam Duchez V
    Ann Biol Clin (Paris); 2020 Feb; 78(1):27-34. PubMed ID: 32108577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.
    Levine MN; Hirsh J; Gent M; Turpie AG; Cruickshank M; Weitz J; Anderson D; Johnson M
    Arch Intern Med; 1994 Jan; 154(1):49-56. PubMed ID: 8267489
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dalteparin dose-dependently increases ROTEM(®) thrombelastography parameters only at supratherapeutic anti-factor Xa levels: an in vitro study.
    Feuring M; Wehling M; Schultz A
    Clin Exp Pharmacol Physiol; 2011 Nov; 38(11):783-6. PubMed ID: 21883380
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays.
    Kitchen S; Preston FE
    Thromb Haemost; 1996 May; 75(5):734-9. PubMed ID: 8725715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discordance between aPTT and anti-Xa in monitoring heparin anticoagulation in mechanical circulatory support.
    Li S; Li A; Beckman JA; Kim C; Granich MA; Mondin J; Sabath DE; Garcia DA; Mahr C
    ESC Heart Fail; 2024 Oct; 11(5):2742-2748. PubMed ID: 38725133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of anti-Xa assay to monitor intravenous unfractionated heparin therapy.
    Rosenberg AF; Zumberg M; Taylor L; LeClaire A; Harris N
    J Pharm Pract; 2010 Jun; 23(3):210-6. PubMed ID: 21507816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monitoring unfractionated heparin therapy: relationship between eight anti-Xa assays and a protamine titration assay.
    Kitchen S; Theaker J; Preston FE
    Blood Coagul Fibrinolysis; 2000 Mar; 11(2):137-44. PubMed ID: 10759006
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of red blood cell transfusion utilization between anti-activated factor X and activated partial thromboplastin monitoring in patients receiving unfractionated heparin.
    Belk KW; Laposata M; Craver C
    J Thromb Haemost; 2016 Nov; 14(11):2148-2157. PubMed ID: 27543785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monitoring of unfractionated heparin with rotational thrombelastometry using the prothrombinase-induced clotting time reagent (PiCT®).
    Schaden E; Jilch S; Hacker S; Schober A; Kozek-Langenecker S
    Clin Chim Acta; 2012 Dec; 414():202-5. PubMed ID: 23041210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The influence of free hemoglobin and bilirubin on heparin monitoring by activated partial thromboplastin time and anti-Xa assay.
    Kostousov V; Nguyen K; Hundalani SG; Teruya J
    Arch Pathol Lab Med; 2014 Nov; 138(11):1503-6. PubMed ID: 25357112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.